GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
1-Year Est. Return
49.13%
1 Year Est. Return
+49.13%
AUM
$276M
AUM Growth
-$11.6M
(-4%)
Holding
70
Top Buys
| 1 | +$13.1M | |
| 2 | +$9.25M | |
| 3 | +$8.12M | |
| 4 |
Janux Therapeutics
JANX
|
+$6.36M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$5.2M |
Top Sells
| 1 | +$17M | |
| 2 | +$11.7M | |
| 3 | +$8.65M | |
| 4 |
Vaxcyte
PCVX
|
+$8M |
| 5 |
Soleno Therapeutics
SLNO
|
+$7.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Taysha Gene Therapies
TSHA
$1.24B
| $4.32M | 1.31% |
2,150,000
+900,000
|
|
||
27
Rhythm Pharmaceuticals
RYTM
$7.2B
| $4.13M | 1.25% |
78,842
-38,546
|
|
||
28
Annexon
ANNX
$623M
| $3.85M | 1.16% |
650,000
+340,000
|
|
||
29
Korro Bio
KRRO
$51.6M
| $3.68M | 1.11% |
110,000
+10,000
|
|
||
30
Dyne Therapeutics
DYN
$3.02B
| $3.59M | 1.09% |
+100,000
|
|
||
31
Arvinas
ARVN
$767M
| $3.57M | 1.08% |
145,000
+70,000
|
|
||
32
Corbus Pharmaceuticals
CRBP
$193M
| $3.3M | 1% |
160,000
-15,000
|
|
||
|
BBOT
33
BridgeBio Oncology
BBOT
$932M
| $3.13M | 0.95% |
300,000
|
|
||
34
Nuvation Bio
NUVB
$2.72B
| $3.09M | 0.93% |
1,350,000
+200,000
|
|
||
35
Savara
SVRA
$1.19B
| $3.07M | 0.93% |
725,000
-325,876
|
|
||
36
Tenaya Therapeutics
TNYA
$215M
| $2.9M | 0.87% |
1,500,000
+150,000
|
|
||
37
Regenxbio
RGNX
$649M
| $2.78M | 0.84% |
265,000
+95,000
|
|
||
38
Corvus Pharmaceuticals
CRVS
$662M
| $2.64M | 0.8% |
+500,000
|
|
||
39
Absci
ABSI
$459M
| $2.1M | 0.63% |
+550,000
|
|
||
40
Neurogene
NGNE
$316M
| $2.1M | 0.63% |
50,000
-20,000
|
|
||
41
Capricor Therapeutics
CAPR
$266M
| $1.9M | 0.57% |
+125,000
|
|
||
42
Apellis Pharmaceuticals
APLS
$2.68B
| $1.87M | 0.57% |
65,000
-70,000
|
|
||
43
Summit Therapeutics
SMMT
$13.2B
| $1.86M | 0.56% |
+85,000
|
|
||
44
Spyre Therapeutics
SYRE
$2.29B
| $1.76M | 0.53% |
60,000
-190,237
|
|
||
45
Viridian Therapeutics
VRDN
$3B
| $1.71M | 0.52% |
75,000
-512,708
|
|
||
46
ProQR Therapeutics
PRQR
$233M
| $1.62M | 0.49% |
887,700
-12,300
|
|
||
|
ATYR
47
aTyr Pharma
ATYR
$76.6M
| $1.41M | 0.43% |
800,000
|
|
||
48
Larimar Therapeutics
LRMR
$314M
| $1.31M | 0.4% |
+200,000
|
|
||
49
enGene Holdings
ENGN
$537M
| $1.06M | 0.32% |
160,898
-259,433
|
|
||
50
Amylyx Pharmaceuticals
AMLX
$1.57B
| $1.05M | 0.32% |
+325,000
|
|